Serologic markers of Chlamydia trachomatis and other sexually transmitted infections and subsequent ovarian cancer risk: Results from the EPIC cohort.
Adult
Aged
Aged, 80 and over
Biomarkers
/ blood
Carcinoma, Ovarian Epithelial
/ blood
Case-Control Studies
Chlamydia Infections
/ blood
Chlamydia trachomatis
/ pathogenicity
Female
Human papillomavirus 16
/ pathogenicity
Humans
Middle Aged
Mycoplasma genitalium
/ pathogenicity
Ovarian Neoplasms
/ blood
Papillomavirus Infections
/ blood
Prospective Studies
Risk
Risk Factors
Sexually Transmitted Diseases
/ blood
Chlamydia trachomatis
Mycoplasma genitalium
herpes simplex virus
human papillomavirus
ovarian cancer
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
15 10 2020
15 10 2020
Historique:
received:
25
09
2019
revised:
23
01
2020
accepted:
19
02
2020
pubmed:
4
4
2020
medline:
13
4
2021
entrez:
4
4
2020
Statut:
ppublish
Résumé
A substantial proportion of epithelial ovarian cancer (EOC) arises in the fallopian tube and other epithelia of the upper genital tract; these epithelia may incur damage and neoplastic transformation after sexually transmitted infections (STI) and pelvic inflammatory disease. We investigated the hypothesis that past STI infection, particularly Chlamydia trachomatis, is associated with higher EOC risk in a nested case-control study within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort including 791 cases and 1669 matched controls. Serum antibodies against C. trachomatis, Mycoplasma genitalium, herpes simplex virus type 2 (HSV-2) and human papillomavirus (HPV) 16, 18 and 45 were assessed using multiplex fluorescent bead-based serology. Conditional logistic regression was used to estimate relative risks (RR) and 95% confidence intervals (CI) comparing women with positive vs. negative serology. A total of 40% of the study population was seropositive to at least one STI. Positive serology to C. trachomatis Pgp3 antibodies was not associated with EOC risk overall, but with higher risk of the mucinous histotype (RR = 2.30 [95% CI = 1.22-4.32]). Positive serology for chlamydia heat shock protein 60 (cHSP60-1) was associated with higher risk of EOC overall (1.36 [1.13-1.64]) and with the serous subtype (1.44 [1.12-1.85]). None of the other evaluated STIs were associated with EOC risk overall; however, HSV-2 was associated with higher risk of endometrioid EOC (2.35 [1.24-4.43]). The findings of our study suggest a potential role of C. trachomatis in the carcinogenesis of serous and mucinous EOC, while HSV-2 might promote the development of endometrioid disease.
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2042-2052Subventions
Organisme : Medical Research Council
ID : 1000143
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N003284/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M012190/1
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 14136; C570/A16491; C8221/A19170
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0401527
Pays : United Kingdom
Organisme : Medical Research Council
ID : G1000143
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 14136
Pays : United Kingdom
Organisme : European Research Council
ID : ERC-2009-AdG 232997
Pays : International
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
Références
Kurman RJ, Shih IM. The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded. Am J Pathol. 2016;186:733-747.
Vang R, Shih Ie M, Kurman RJ. Fallopian tube precursors of ovarian low- and high-grade serous neoplasms. Histopathology. 2013;62:44-58.
Fadare O, Parkash V. Pathology of endometrioid and clear cell carcinoma of the ovary. Surg Pathol Clin. 2019;12:529-564.
Wentzensen N, Poole EM, Trabert B, et al. Ovarian cancer risk factors by histologic subtype: an analysis from the Ovarian Cancer Cohort Consortium. J Clin Oncol. 2016;34:2888-2898.
Labidi-Galy SI, Papp E, Hallberg D, et al. High grade serous ovarian carcinomas originate in the fallopian tube. Nat Commun. 2017;8:1093.
Haggerty CL, Taylor BD. Mycoplasma genitalium: an emerging cause of pelvic inflammatory disease. Infect Dis Obstet Gynecol. 2011;2011:959816.
Mitchell C, Prabhu M. Pelvic inflammatory disease: current concepts in pathogenesis, diagnosis and treatment. Infect Dis Clin North Am. 2013;27:793-809.
Lin HW, Tu YY, Lin SY, et al. Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study. Lancet Oncol. 2011;12:900-904.
Stewart LM, Spilsbury K, Jordan S, et al. Risk of high-grade serous ovarian cancer associated with pelvic inflammatory disease, parity and breast cancer. Cancer Epidemiol. 2018;55:110-116.
Rasmussen CB, Kjaer SK, Albieri V, et al. Pelvic inflammatory disease and the risk of ovarian cancer and borderline ovarian tumors: a pooled analysis of 13 case-control studies. Am J Epidemiol. 2017;185:8-20.
Patton DL, Landers DV, Schachter J. Experimental Chlamydia trachomatis salpingitis in mice: initial studies on the characterization of the leukocyte response to chlamydial infection. J Infect Dis. 1989;159:1105-1110.
Patton DL, Halbert SA, Kuo CC, et al. Host response to primary Chlamydia trachomatis infection of the fallopian tube in pig-tailed monkeys. Fertil Steril. 1983;40:829-840.
Karim S, Souho T, Benlemlih M, Bennani B. Cervical cancer induction enhancement potential of Chlamydia trachomatis: a systematic review. Curr Microbiol. 2018;75:1667-1674.
Namiki K, Goodison S, Porvasnik S, et al. Persistent exposure to mycoplasma induces malignant transformation of human prostate cells. PLoS One. 2009;4:e6872.
Li S, Wen X. Seropositivity to herpes simplex virus type 2, but not type 1 is associated with cervical cancer: NHANES (1999-2014). BMC Cancer. 2017;17:726.
Yang EJ, Quick MC, Hanamornroongruang S, et al. Microanatomy of the cervical and anorectal squamocolumnar junctions: a proposed model for anatomical differences in HPV-related cancer risk. Mod Pathol. 2015;28:994-1000.
Seidman JD, Yemelyanova A, Zaino RJ, Kurman RJ. The fallopian tube-peritoneal junction: a potential site of carcinogenesis. Int J Gynecol Pathol. 2011;30:4-11.
Trabert B, Waterboer T, Idahl A, et al. Antibodies against Chlamydia trachomatis and ovarian cancer risk in two independent populations. J Natl Cancer Inst. 2019;111:129-136.
Ness RB, Goodman MT, Shen C, Brunham RC. Serologic evidence of past infection with Chlamydia trachomatis, in relation to ovarian cancer. J Infect Dis. 2003;187:1147-1152.
Ness RB, Shen C, Bass D, et al. Chlamydia trachomatis serology in women with and without ovarian cancer. Infect Dis Obstet Gynecol. 2008;2008:219672.
Idahl A, Lundin E, Elgh F, et al. Chlamydia trachomatis, Mycoplasma genitalium, Neisseria gonorrhoeae, human papillomavirus, and polyomavirus are not detectable in human tissue with epithelial ovarian cancer, borderline tumor, or benign conditions. Am J Obstet Gynecol. 2010;202:71.e71-71.e76.
Idahl A, Lundin E, Jurstrand M, et al. Chlamydia trachomatis and Mycoplasma genitalium plasma antibodies in relation to epithelial ovarian tumors. Infect Dis Obstet Gynecol. 2011;2011:824627.
Jonsson S, Oda H, Lundin E, et al. Chlamydia trachomatis, chlamydial heat shock protein 60 and anti-chlamydial antibodies in women with epithelial ovarian tumors. Transl Oncol. 2018;11:546-551.
Wong A, Maclean AB, Furrows SJ, et al. Could epithelial ovarian cancer be associated with chlamydial infection? Eur J Gynaecol Oncol. 2007;28:117-120.
Fortner RT, Terry KL, Bender N, et al. Sexually transmitted infections and risk of epithelial ovarian cancer: results from the Nurses’ Health Studies. Br J Cancer. 2019;120:855-860.
Hisada M, van den Berg BJ, Strickler HD, et al. Prospective study of antibody to human papilloma virus type 16 and risk of cervical, endometrial, and ovarian cancers (United States). Cancer Causes Control. 2001;12:335-341.
Riboli E, Hunt KJ, Slimani N, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr. 2002;5:1113-1124.
Terry KL, Schock H, Fortner RT, et al. A prospective evaluation of early detection biomarkers for ovarian cancer in the European EPIC cohort. Clin Cancer Res. 2016;22:4664-4675.
Waterboer T, Sehr P, Michael KM, et al. Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. Clin Chem. 2005;51:1845-1853.
Hulstein SH, Matser A, Alberts CJ, et al. Differences in Chlamydia trachomatis seroprevalence between ethnic groups cannot be fully explained by socioeconomic status, sexual healthcare seeking behavior or sexual risk behavior: a cross-sectional analysis in the HEalthy LIfe in an Urban Setting (HELIUS) study. BMC Infect Dis. 2018;18:612.
Horner PJ, Wills GS, Righarts A, et al. Chlamydia trachomatis Pgp3 antibody persists and correlates with self-reported infection and behavioural risks in a blinded cohort study. PLoS One. 2016;11:e0151497.
Winstanley CE, Ramsey KH, Marsh P, Clarke IN. Development and evaluation of an enzyme-linked immunosorbent assay for the detection of antibodies to a common urogenital derivative of Chlamydia trachomatis plasmid-encoded PGP3. J Immunol Methods. 2017;445:23-30.
Witkin SS, Minis E, Athanasiou A, et al. Chlamydia trachomatis: the persistent pathogen. Clin Vaccine Immunol. 2017;24:e00203-17.
Brenner N, Mentzer AJ, Butt J, et al. Validation of multiplex serology detecting human herpesviruses 1-5. PLoS One. 2018;13:e0209379.
Wang M, Spiegelman D, Kuchiba A, et al. Statistical methods for studying disease subtype heterogeneity. Stat Med. 2016;35:782-800.
Dean D, Powers VC. Persistent Chlamydia trachomatis infections resist apoptotic stimuli. Infect Immun. 2001;69:2442-2447.
Di Felice V, David S, Cappello F, et al. Is chlamydial heat shock protein 60 a risk factor for oncogenesis? Cell Mol Life Sci. 2005;62:4-9.
Smelov V, Vrbanac A, van Ess EF, et al. Chlamydia trachomatis strain types have diversified regionally and globally with evidence for recombination across geographic divides. Front Microbiol. 2017;8:2195.
Prat J. Pathology of borderline and invasive cancers. Best Pract Res Clin Obstet Gynaecol. 2017;41:15-30.
Kessler M, Hoffmann K, Fritsche K, et al. Chronic Chlamydia infection in human organoids increases stemness and promotes age-dependent CpG methylation. Nat Commun. 2019;10:1194.
Horner PJ, Wills GS, Reynolds R, et al. Effect of time since exposure to Chlamydia trachomatis on chlamydia antibody detection in women: a cross-sectional study. Sex Transm Infect. 2013;89:398-403.
Wills GS, Horner PJ, Reynolds R, et al. Pgp3 antibody enzyme-linked immunosorbent assay, a sensitive and specific assay for seroepidemiological analysis of Chlamydia trachomatis infection. Clin Vaccine Immunol. 2009;16:835-843.